Mundo Sano launches “Not a Single Baby with Chagas” initiative to change the history of Chagas diseaseMiguel Martínez-Cava2019-03-14T14:12:58+01:00March 14, 2019|Read More
Twelve startups present disruptive healthcare solutions at Insud Pharma’s Pitch DayMiguel Martínez-Cava2019-01-31T09:48:49+01:00January 30, 2019|Read More
Publication of the final data from the clinical trial for mAbxience bevacizumab in metastatic colorectal cancer published in The Lancet Gastroenterology & HepatologyMiguel Martínez-Cava2018-09-27T12:05:35+02:00September 27, 2018|Read More
Insud Pharma secures “very good” rating in the Profarma ProgrammeMiguel Martínez-Cava2018-09-24T13:32:46+02:00September 24, 2018|Read More
The Autonomous University of Madrid and Insud Pharma join forces for biomedical innovationMiguel Martínez-Cava2018-09-24T17:54:32+02:00July 16, 2018|Read More
mAbxience and Amneal enter into an agreement for bevacizumab biosimilar in the United StatesMiguel Martínez-Cava2018-09-24T17:54:06+02:00May 23, 2018|Read More
Biosimilars reduce healthcare costs by up to 40% and increase patient accessibility to innovative treatmentsMiguel Martínez-Cava2018-05-07T15:49:40+02:00May 7, 2018|Read More
5th Castilla y León’s Best Director AwardsMiguel Martínez-Cava2018-05-07T15:47:49+02:00April 30, 2018|Read More
Cancer Chemotherapy and Pharmacology has published comparative data of rituximab biosimilar RTXM83R in lymphoma patientsMiguel Martínez-Cava2018-03-06T13:10:49+01:00March 6, 2018|Read More
2nd National Conference on BiosimilarsMiguel Martínez-Cava2018-03-05T10:23:01+01:00March 5, 2018|Read More
